| PCSK9 inhibitors–mechanisms of action MM Page, GF Watts Australian prescriber 39 (5), 164, 2016 | 94 | 2016 |
| Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia GF Watts, DR Sullivan, DL Hare, KM Kostner, AE Horton, DA Bell, T Brett, ... Heart, Lung and Circulation 30 (3), 324-349, 2021 | 92 | 2021 |
| Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children MM Page, DA Bell, AJ Hooper, GF Watts, JR Burnett Best Practice & Research Clinical Endocrinology & Metabolism 28 (3), 387-403, 2014 | 47 | 2014 |
| Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid‐lowering therapies MM Page, EI Ekinci, RM Jones, PW Angus, PJ Gow, RC O'Brien Internal medicine journal 44 (6), 601-604, 2014 | 34 | 2014 |
| PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease MM Page, GF Watts Diabetes, Obesity and Metabolism 20 (2), 270-282, 2018 | 32 | 2018 |
| Improved technical success and radiation safety of adrenal vein sampling using rapid, semi-quantitative point-of-care cortisol measurement MM Page, M Taranto, D Ramsay, G van Schie, P Glendenning, MJ Gillett, ... Annals of clinical biochemistry 55 (5), 588-592, 2018 | 31 | 2018 |
| Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin … MM Page, C Stefanutti, A Sniderman, GF Watts Clinical Science 129 (1), 63-79, 2015 | 28 | 2015 |
| Psychotropic drugs and dentistry MM Page, LM Somerville-Brown Australian Prescriber 30 (4), 98, 2007 | 23 | 2007 |
| Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: a creative approach by a cardiologist in a developing country KL Khoo, MM Page, YM Liew, JC Defesche, GF Watts Journal of clinical lipidology 10 (5), 1188-1194, 2016 | 19 | 2016 |
| Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia MM Page, KL Ellis, J Pang, DC Chan, AJ Hooper, DA Bell, JR Burnett, ... Clinica Chimica Acta 510, 211-215, 2020 | 16 | 2020 |
| Contemporary perspectives on the genetics and clinical use of lipoprotein (a) in preventive cardiology MM Page, GF Watts Current Opinion in Cardiology 36 (3), 272-280, 2021 | 15 | 2021 |
| Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? MM Page, AJ Hooper, JR Burnett Expert Opinion on Pharmacotherapy 17 (2), 275-281, 2016 | 14 | 2016 |
| Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology MM Page, GF Watts Expert Opinion on Drug Metabolism & Toxicology 11 (9), 1505-1515, 2015 | 14 | 2015 |
| Approach to the diagnosis of secondary hypertension in adults R Siru, JH Conradie, MJ Gillett, MM Page Australian prescriber 44 (5), 165, 2021 | 11 | 2021 |
| Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes? MM Page, DA Bell, GF Watts Clinical Genetics 97 (4), 543-555, 2020 | 11 | 2020 |
| PCSK9 inhibition 2018: riding a new wave of coronary prevention NC Ward, MM Page, GF Watts Clinical Science 133 (2), 205-224, 2019 | 11 | 2019 |
| Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention MM Page, GF Watts Expert opinion on emerging drugs 20 (2), 299-312, 2015 | 11 | 2015 |
| Pharmacokinetics of benzylpenicillin (penicillin G) during prolonged intermittent renal replacement therapy V Cheng, M Rawlins, T Chang, E Fox, J Dyer, C Allen, E Litton, MM Page, ... Chemotherapy 64 (1), 17-21, 2019 | 10 | 2019 |
| Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand MM Page, W Hardikar, G Alex, S Bates, S Srinivasan, M Stormon, K Hall, ... Atherosclerosis 387, 117305, 2023 | 8 | 2023 |
| A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia MM Page, KL Ellis, DC Chan, J Pang, AJ Hooper, DA Bell, JR Burnett, ... Journal of Clinical Lipidology 16 (4), 525-529, 2022 | 8 | 2022 |
